Search results for "OUTCOME"

showing 10 items of 5148 documents

The prognostic role of the cardio-ankle vascular index

2018

The well‐performed meta‐analysis of Matsushita et al represents an important contribution to the knowledge about the clinical meaning of arterial stiffness parameters, suggesting that CAVI is associated positively with a slightly increased risk of CV events, but not of total mortality. However, caution is needed in interpreting these findings, due to the limited number of prospective studies eligible for the meta‐analysis and the relatively low number of subjects included, mostly living in Japan or China. Therefore, additional studies, preferably with a prospective design and involving participants also from non‐Asian countries, are required to better define the prognostic role and the clin…

Agingmedicine.medical_specialtyEndocrinology Diabetes and MetabolismHypertension and Cardiovascular OutcomesPulse Wave Analysis030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesVascular Stiffness0302 clinical medicineatherosclerosiMeta-Analysis as TopicRisk FactorsOscillometryInternal medicineInternal MedicinemedicineHypertension generalHumans030212 general & internal medicineCardio-ankle vascular indexhypertension-generalbusiness.industryPrognosisCardio Ankle Vascular IndexCardiovascular DiseasesCardiologyhypertension-vascular diseaseCardiology and Cardiovascular Medicinebusinessarterial complianceAlgorithms
researchProduct

Intermittent intramuscular clodronate therapy: a valuable option for older osteoporotic women

2005

Agingmedicine.medical_specialtyOsteoporosisTreatment outcomeMEDLINE.Injections IntramuscularDrug Administration Schedulelaw.inventionPhysical medicine and rehabilitationPharmacotherapyRandomized controlled triallawBone DensitymedicineHumansFemurVitamin DOsteoporosis PostmenopausalAgedPain MeasurementLumbar Vertebraecalcium clodronic acid vitamin DBone Density Conservation Agentsbusiness.industryGeneral Medicinemedicine.diseaseTreatment OutcomeBack PainPhysical therapyCalciumDrug Therapy CombinationFemaleGeriatrics and GerontologyClodronic Acidbusiness
researchProduct

Combined resistance and balance-jumping exercise reduces older women's injurious falls and fractures: 5-year follow-up study

2014

BACKGROUND AND OBJECTIVE: previously, a randomised controlled exercise intervention study (RCT) showed that combined resistance and balance-jumping training (COMB) improved physical functioning and bone strength. The purpose of this follow-up study was to assess whether this exercise intervention had long-lasting effects in reducing injurious falls and fractures. DESIGN: five-year health-care register-based follow-up study after a 1-year, four-arm RCT. SETTING: community-dwelling older women in Finland. SUBJECTS: one hundred and forty-five of the original 149 RCT participants; women aged 70-78 years at the beginning. METHODS: participants' health-care visits were collected from computerised…

Agingmedicine.medical_specialtyTime FactorsPoison controlKaplan-Meier Estimatelaw.inventionFractures Bonesymbols.namesakeRandomized controlled trialRisk FactorslawOdds RatiomedicineHumansMuscle StrengthProspective StudiesRegistriesPoisson regressionProspective cohort studyGeriatric AssessmentPostural BalanceExerciseFinlandAgedProportional Hazards ModelsProportional hazards modelbusiness.industryIncidenceHazard ratioAge FactorsResistance Trainingta3141General MedicineOdds ratioInjurious fallsTreatment OutcomeOlder adultsRelative risksymbolsPhysical therapyWomen's HealthAccidental FallsFemaleIndependent LivingGeriatrics and GerontologybusinessFracturesFollow-Up StudiesAge and Ageing
researchProduct

GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.

2009

The use of gonadotrophin-releasing hormone (GnRH) agonists for triggering ovulation remains controversial. The primary objective of this study was to evaluate the incidence of ovarian hyperstimulation syndrome (OHSS) following GnRH agonist versus recombinant human chorionic gonadotrophin (HCG) as methods for triggering ovulation. A second aim was to compare the clinical outcome and embryo quality according to the two procedures. The cycle characteristics of 100 oocyte donors undergoing ovarian stimulation and IVF outcomes of their 100 oocyte recipients were analysed. Donors were prospectively randomized into two groups on the last day of ovarian stimulation: Group I received a single bolus …

AgonistAdultendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectOvarian hyperstimulation syndromeFertilization in VitroChorionic GonadotropinAndrologyGonadotropin-Releasing HormoneOvarian Hyperstimulation SyndromeOvulation InductionPregnancymedicineHumansOvulationmedia_commonGynecologyPregnancyIn vitro fertilisationTriptorelin PamoateOocyte Donationbusiness.industryObstetrics and GynecologyOocytemedicine.diseaseTriptorelinRecombinant Proteinsmedicine.anatomical_structureTreatment OutcomeReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsEmbryo qualityDevelopmental Biologymedicine.drugReproductive biomedicine online
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.

2007

Liver or lung metastases usually relapse under chemotherapy. Such life-threatening condition urgently needs new, systemic anticancer compounds, with original and efficient mechanisms of action. In B16 melanoma mice treated with cyclophosphamide, D'Agostini et al. [D'Agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., Garaci, E., 2005. Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5, 1205-1212.] recently found that OM-174, a chemically defined Toll-like receptor(TLR)2/4 agonist, reduces tumor progression and prolongs survival. Here we review 149 articles concerning molecular mechanisms of TLR2…

AgonistLipopolysaccharidesCyclophosphamidemedicine.drug_classmedicine.medical_treatmentNitric Oxide Synthase Type IIAntineoplastic AgentsApoptosisNitric oxidechemistry.chemical_compoundRecurrenceNeoplasmsMedicineAnimalsHumansPharmacologyChemotherapybusiness.industryTumor Necrosis Factor-alphaCancerDendritic Cellsmedicine.diseaseNeoadjuvant TherapyToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4TLR2Lipid ATreatment OutcomechemistryTumor progressionChemotherapy AdjuvantDrug Resistance NeoplasmEnzyme InductionImmunologyCancer researchBCG VaccineTumor necrosis factor alphaImmunotherapybusinessmedicine.drugSignal TransductionT-Lymphocytes CytotoxicEuropean journal of pharmacology
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms

1994

Twenty schizophrenic inpatients with either predominantly positive or predominantly negative symptoms were treated with the dopamine autoreceptor agonist roxindole in prospective open clinical trials. There was no antipsychotic effect in the subgroup with positive symptoms, whereas the subgroup with negative symptoms, especially those with the residual type of schizophrenia, showed a moderate but significant 20% reduction in total scores on the Scale for the Assessment of Negative Symptoms.

Agonistmedicine.medical_specialtyPsychosismedicine.drug_classDopamine AgentsGastroenterologyReceptors Dopaminechemistry.chemical_compoundRoxindoleInternal medicinemental disordersSchizophrenic PsychologymedicineHumansProspective StudiesScale for the Assessment of Negative SymptomsPsychiatric Status Rating ScalesSchizophrenia ParanoidDose-Response Relationship Drugbusiness.industrymedicine.diseaseHospitalizationPsychiatry and Mental healthTreatment OutcomeEndocrinologychemistrySchizophreniaDopamine receptorSchizophreniaAutoreceptorSchizophrenic PsychologybusinessAmerican Journal of Psychiatry
researchProduct

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of…

2019

ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children <3 years.ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body ma…

Alcoholic liver diseasemedicine.medical_specialtyobesitybifidobacteriumGastroenterology03 medical and health sciences0302 clinical medicineInsulin resistanceDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumans030212 general & internal medicine1506BifidobacteriumRandomized Controlled Trials as Topic2. Zero hunger[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismNutrition and Metabolismbiologydiabetesbusiness.industryProbioticsResearchFatty livernon-alcoholic fatty liver diseaseGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseasebiology.organism_classificationPolycystic ovaryObesity3. Good healthlactobacillus[SDV.AEN] Life Sciences [q-bio]/Food and NutritionTreatment Outcome[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieDietary Supplements[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie1714businessBody mass index[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryBMJ open
researchProduct

Current therapeutical strategies for allergic rhinitis

2018

Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option.This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the…

Allergen immunotherapyRhinitis allergicTreatment outcomeHistamine Antagonistsmacromolecular substancesmedicine.disease_cause03 medical and health sciences0302 clinical medicineAllergenimmune system diseasesmedicineHumansPharmacology (medical)AsthmaPharmacologybusiness.industryHistamine antagonistsGeneral MedicineAtopic dermatitisrespiratory systemmedicine.diseaseRhinitis Allergicrespiratory tract diseasesbody regionsTreatment OutcomeDesensitization Immunologic030220 oncology & carcinogenesisImmunologybusiness030217 neurology & neurosurgeryExpert Opinion on Pharmacotherapy
researchProduct